BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Top 15 Style Creators Changing the Business - 2Rick Steves Prefers Paying A Bit Extra For This Delectable Food When Dining In Spain
- 321 Incredibly Interesting Contemplations To Observe Consistently
- 4Building a Flourishing Business: Illustrations from Business people
- 5Productive CRM Programming for Client Relationship The executives
- The Main 15 Applications for Efficiency and Association
- Unsold Rams May Be Less expensive Than You Suspect
- Style Narratives: A Survey of \Patterns and Styles Assessed\ Design
- 7 Powerful Techniques to Boost Efficiency with Your Cell Phone: A Far reaching Guide
- Heartfelt Objections to Visit with Your Adored One
- The most effective method to Use an Internet Showcasing Degree for Advanced Predominance
- Flu surges across U.S. as doctor visits reach highest level since 1997
- Flu cases skyrocket in US. See cases, where people got sick.
- Selena Quintanilla documentary 'Selena y Los Dinos: A Family's Legacy' is coming to Netflix
